Durvalumab vs Tirzepatide

## Durvalumab vs Tirzepatide: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Tirzepatide**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

**Tirzepatide**: Dual GIP and GLP-1 receptor agonist.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Tirzepatide — 5 days.

## Chemical Properties

**Type**: Durvalumab — Antibody; Tirzepatide — Protein.